From Surf Wiki (app.surf) — the open knowledge base
Cethromycin
Chemical compound
Chemical compound
| Field | Value | |||
|---|---|---|---|---|
| Verifiedfields | changed | |||
| Watchedfields | changed | |||
| verifiedrevid | 445236160 | |||
| IUPAC_name | (1S,2R,5R,7R,8R,9S,11R,13R,14R)-8-[(2S,3R,4S,6R)- 4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13- hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy] -3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone | |||
| image | Cethromycin1.svg | |||
| image_class | skin-invert-image | |||
| pregnancy_AU | ||||
| pregnancy_US | ||||
| legal_AU | ||||
| legal_CA | ||||
| legal_UK | ||||
| legal_US_comment | Phase III Clinical Trials | |||
| routes_of_administration | Oral | |||
| bioavailability | Between 35.8 and 60% in animal studies. | |||
| metabolism | Liver | |||
| elimination_half-life | 1.6, 3.0, 4.5, 5.9 and 6 hours. Mouse, Monkey, Rat, Dog and Human respectively. | |||
| excretion | 7.0% urine 87.2% faeces | |||
| CAS_number_Ref | ||||
| CAS_number | 205110-48-1 | |||
| ATC_prefix | none | |||
| PubChem | 5282045 | |||
| ChEBI | 29506 | |||
| DrugBank_Ref | ||||
| ChEMBL_Ref | ||||
| ChEMBL | 365528 | |||
| UNII_Ref | ||||
| UNII | J0086219X6 | |||
| KEGG_Ref | ||||
| KEGG | D02391 | ChemSpiderID_Ref = | ||
| ChemSpiderID | 23258189 | |||
| smiles | CC[C@@H]1[C@@]2(C@@HNC(=O)O2)C | |||
| StdInChI_Ref | ||||
| StdInChI | 1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/b15-14+/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41+,42-/m1/s1 | |||
| StdInChIKey_Ref | ||||
| StdInChIKey | PENDGIOBPJLVBT-HMMOOPTJSA-N | |||
| C | 42 | H=59 | N=3 | O=10 |
| melting_point | 211 | |||
| melting_high | 213 |
| elimination_half-life = 1.6, 3.0, 4.5, 5.9 and 6 hours. Mouse, Monkey, Rat, Dog and Human respectively.
Cethromycin, trade name Restanza (initially known as ABT-773{{cite journal |doi-access=free
On October 1, 2008, Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.
On December 3, 2008, Advanced Life Sciences announced that this New Drug Application has been accepted for filing by the FDA.
In June 2009, an FDA Anti-Infective Drugs Advisory Committee review found insufficient evidence for cethromycin efficacy in treatment of community acquired pneumonia, as the Phase 3 clinical trial followed standards that were updated after the clinical trial but three months prior to review. The committee did, however, find the drug safe to use.
References
References
- link. (April 20, 2008)
- [https://www.drugs.com/nda/cethromycin_081001.html Cethromycin New Drug Application]
- (June 2019)
- Advanced Life Sciences Holdings, Inc.. "Complete Response Letter for Restanza NDA". Drugs.com.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Cethromycin — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report